TEVA-GALANTAMINE ER 8 MG
GALANTAMINE (GALANTAMINE HYDROBROMIDE) : 8 MG · DIN 02377950 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is TEVA-GALANTAMINE ER?
TEVA-GALANTAMINE ER 8 MG contains GALANTAMINE (GALANTAMINE HYDROBROMIDE) : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02377950, held by TEVA CANADA LIMITED, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 22-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02377950 |
|---|---|
| Brand name | TEVA-GALANTAMINE ER |
| Generic / active ingredient | GALANTAMINE (GALANTAMINE HYDROBROMIDE) : 8 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 8 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06DA04 GALANTAMINE |
| AHFS class | 12:04.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 22-Jun-2018 |
| Original market date | 2012-01-06 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N06DA04 GALANTAMINE. 12 of 46 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02425165 |
| AURO-GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02425173 |
| AURO-GALANTAMINE ER | 8 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02425157 |
| GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02443023 |
| GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02443031 |
| GALANTAMINE ER | 8 MG | CAPSULE (EXTENDED RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02443015 |
| MYLAN-GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02339447 |
| MYLAN-GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02339455 |
| MYLAN-GALANTAMINE ER | 8 MG | CAPSULE (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02339439 |
| PAT-GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | JANSSEN INC | MARKETED | DIN 02316951 |
Who else supplies GALANTAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GALANTAMINE appears in 4804 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.